DDAVP

What it is

DDAVP — formally 1-deamino-8-D-arginine vasopressin, the international nonproprietary name desmopressin — is a synthetic analog of arginine vasopressin (AVP, antidiuretic hormone). Two structural modifications differentiate it from native vasopressin:

• Deamination at the N-terminal cysteine, which extends half-life by reducing enzymatic degradation.
• Substitution of the L-arginine at position 8 with D-arginine, which substantially reduces V1 receptor binding (and therefore pressor effects) while preserving V2 receptor activity (and therefore antidiuretic effects).

The result is a peptide with the antidiuretic potency of vasopressin but minimal pressor activity, making it suitable for chronic use in conditions of antidiuretic hormone deficiency or for situations in which renal water conservation or factor VIII release is desired.

History

Desmopressin was synthesized in 1967 by Zaoral, Kolc, and Šorm at the Czechoslovak Academy of Sciences. Ferring Pharmaceuticals subsequently developed the compound and brought it through regulatory review. The FDA approved DDAVP intranasal spray in 1978 for central diabetes insipidus and primary nocturnal enuresis, with later approvals for hemophilia A and type 1 von Willebrand disease. Oral tablets followed in the 1990s. Nocdurna, a sex-specific sublingual lyophilizate for nocturia (with separate dose recommendations for men and women due to differential hyponatremia risk), was approved in 2018.

International societies — including the International Children's Continence Society — have produced standardization documents on the use of desmopressin in pediatric nocturnal enuresis, most recently in 2020.

Regulatory status

DDAVP is FDA-approved in multiple formulations for several indications:

• Central diabetes insipidus. Intranasal, oral, and IV forms.
• Primary nocturnal enuresis in children aged 6 and older. Intranasal and oral forms.
• Mild hemophilia A and type 1 von Willebrand disease. IV form, given before invasive procedures or to manage bleeding episodes, leveraging desmopressin's release of factor VIII and von Willebrand factor from endothelial stores.
• Nocturia in adults with at least two voids per night (Nocdurna sublingual).

Approvals exist by EMA, MHRA, Health Canada, and most major regulators. The intranasal product for nocturnal enuresis was withdrawn for that pediatric indication in some jurisdictions due to hyponatremia risk; oral formulations are preferred in many guidelines.

Mechanism

DDAVP is selective for the V2 vasopressin receptor, expressed primarily in:

• Renal collecting duct cells. V2 activation triggers insertion of aquaporin-2 water channels into the apical membrane, increasing water reabsorption and concentrating urine. This is the basis for use in central diabetes insipidus, nocturnal enuresis, and nocturia.
• Vascular endothelium. V2 activation releases factor VIII and von Willebrand factor from Weibel-Palade bodies into circulation. This is the basis for use before procedures in mild hemophilia A and type 1 von Willebrand disease.

The selectivity profile — high V2, low V1 — distinguishes desmopressin from native vasopressin, which is used in different clinical contexts (vasodilatory shock, certain cardiac arrest scenarios) for its pressor activity.

Half-life and dosing intervals

Published half-life:

• Intranasal: approximately 2.8 hours.
• Oral: approximately 2.5–3 hours.
• IV: approximately 0.4–4 hours depending on dose and clearance.

The duration of antidiuretic effect typically exceeds the plasma half-life and is generally 6–14 hours, making once- or twice-daily intranasal or oral dosing appropriate for most chronic indications.

Approved dose ranges per the FDA labels:

• Central diabetes insipidus, intranasal: 10–40 mcg per day in 1–3 divided doses.
• Primary nocturnal enuresis, oral: 0.2 mg at bedtime, may titrate up to 0.6 mg.
• Nocturia (Nocdurna): 27.7 mcg (women) or 55.3 mcg (men) sublingually one hour before bedtime.
• Hemophilia A / vWD, IV: 0.3 mcg per kilogram in 50 mL saline over 15–30 minutes.

Reconstitution example

Intranasal DDAVP is supplied as a buffered solution, commonly 100 mcg/mL. A standard nasal spray actuation delivers approximately 10 mcg. Oral tablets (0.1 mg, 0.2 mg) and the sublingual Nocdurna lyophilizate are commercially formulated and require no reconstitution.

For research preparations of desmopressin not in finished dosage form, suppliers typically provide a lyophilized powder. A 1 mg vial reconstituted with 2 mL of bacteriostatic water yields 500 mcg/mL — well above approved daily doses; volumes used in approved indications are correspondingly small.

What to know

• Hyponatremia is the principal risk. Excess water retention can produce dilutional hyponatremia, which in severe cases can cause seizures. Fluid restriction at the time of dosing is part of every approved indication, and Nocdurna's sex-specific dose reflects higher hyponatremia risk in women.
• Drug interactions. Tricyclic antidepressants, SSRIs, NSAIDs, opioids, and chlorpromazine can potentiate the antidiuretic effect.
• Hemophilia use is procedure-specific. IV desmopressin before dental, surgical, or other invasive procedures works in patients with mild hemophilia A or type 1 vWD; it is ineffective in severe disease and is not a substitute for factor concentrate.
• Storage. Intranasal and oral products: refrigerate per label; some preparations are stable at room temperature for limited periods after opening.
• Reported side effects. Common observations in trials and post-marketing include headache, nausea, nasal congestion (intranasal), and dose-dependent hyponatremia. Cardiovascular and neurological effects of significant hyponatremia are the principal serious adverse events.